Compare Ambarella Inc (AMBA) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.

Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.